MART1 (27-35) HLA-A*02:01 流式验证

靶点说明

MART1 (27-35) AAGIGILTV HLA-A*02:01

HLA类型

HLA-A*02:01, 中国人分布频率12.036%

抗原和HLA的亲和力

NetMHCpan 4.1  计算AAGIGILTV与HLA-A*02:01亲和力为 3874.86 nM。

产品类型和应用

产品类型规格价格
流式检测与分选MART1 (27-35) HLA-A*02:01 PE / APC / Alexa Fluor 4887200元/50ug, 11800元/100ug
磁珠分选MART1 (27-35) HLA-A*02:01 HLA-A*02:01磁珠8200元/50ug, 12800元/100ug
生物素化复合物MART1 (27-35) HLA-A*02:01 HLA-A*02:01-biotin6800元/50ug, 11400元/100ug

实测结果

肽刺激PBMC后检测抗原特异性CD8+T细胞

AAGIGILTV多肽刺激HLA-A*02:01限制性PBMC后,使用MART1 (27-35) HLA-A*02:01 PE 四聚体和抗CD8-FITC抗体检测。下图左图为抗原肽AAGIGILTV刺激组,右图为未加抗原肽刺激组。

靶点结合的TCR序列

请查看IEDB数据库

相关文章

Reference - PMIDReference - JournalReference - DateReference - Title
7706734J Immunol1995Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
7868898J Immunol1995Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
8938271Semin Cancer Biol1995Epitope selection and development of peptide based vaccines to treat cancer.
9862732J Immunol1998HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
10540322Eur J Immunol1999H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.
12972191J Immunol Methods2003In situ detection of antigen-specific tumor-infiltrating lymphocytes using newly designed tetramers.
15723046Nat Biotechnol2005Directed evolution of human T-cell receptors with picomolar affinities by phage display.
18424733J Immunol2008Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
16197958J Mol Biol2005Unraveling a hotspot for TCR recognition on HLA-A2: evidence against the existence of peptide-independent TCR binding determinants.
17719062J Mol Biol2007Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
16455990J Immunol2006Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex.
10958352Tissue Antigens2000Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules.
21093097Immunobiology2011IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.
17056587J Immunol2006Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
18942640Prostate2009The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
22952231J Biol Chem2012T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting.
24550723PLoS Comput Biol2014Computational design of the affinity and specificity of a therapeutic T cell receptor.
21795600J Immunol2011TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms.
25198529J Immunother2014TCR+CD4-CD8- T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation.
11886495J Invest Dermatol2001Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice.
25505266J Biol Chem2015Naturally processed non-canonical HLA-A*02:01 presented peptides.
25589627Clin Cancer Res2015Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.
28489076Nat Commun2017HLA-DP<sup>84Gly</sup> constitutively presents endogenous peptides generated by the class I antigen processing pathway.
10916751J Immunother2000Quantitation of T-cell receptor frequencies by competitive polymerase chain reaction: dynamics of T-cell clonotype frequencies in an expanding tumor-infiltrating lymphocyte culture.
21937447J Biol Chem2011Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design.
23954306J Mol Biol2013Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.
30425106Cancer Immunol Res2019High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.
30700903Nat Methods2019T cell antigen discovery via trogocytosis.
30617019Mol Ther2019Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.
31091334Eur J Immunol2019TCR-induced alteration of primary MHC peptide anchor residue.
32184297Cancer Immunol Res2020Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform.
32314731Elife2020Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
11684128J Immunol Methods2001Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells.
32241816Clin Cancer Res2020Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells.
34290406Nature2021Phenotype, specificity and avidity of antitumour CD8<sup>+</sup> T cells in melanoma.
36608422Mol Immunol2023ERAP2 supports TCR recognition of three immunotherapy targeted tumor epitopes.
35874702Front Immunol2022Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
35508657Nature2022Landscape of helper and regulatory antitumour CD4<sup>+</sup> T cells in melanoma.
37490916Cell2023Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.
26079729J Immunol Methods2015Unpredicted phenotypes of two mutants of the TcR DMF5.
23391568Hum Immunol2013Analyses of T cell-mediated immune response to a human melanoma-associated antigen by the young and the elderly.

滚动至顶部